Synthetic peptide conjugated to KLH derived from within residues 150 - 250 of Human SMURF1 .
This antibody gave a positive signal in Human bone tumour tissue lysate as well as the following whole cell lysates: HeLa; U20S; MG-63; Saos2.
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Preservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
Immunogen affinity purified
Immunizing Peptide (Blocking)
Abpromise guarantee covers the use of
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 1 µg/ml. Detects a band of approximately 86 kDa (predicted molecular weight: 86 kDa).
E3 ubiquitin-protein ligase that acts as a negative regulator of BMP signaling pathway. Acts by mediating ubiquitination and degradation of SMAD1 and SMAD5, 2 receptor-regulated SMADs specific for the BMP pathway. Promotes ubiquitination and subsequent proteasomal degradation of TRAF family members.
Protein modification; protein ubiquitination.
Contains 1 C2 domain.
Contains 1 HECT (E6AP-type E3 ubiquitin-protein ligase) domain. Contains 2 WW domains.
Ubiquitinated by the SCF(FBXL15) complex at Lys-381 and Lys-383, leading to its degradation by the proteasome. Lys-383 is the primary ubiquitination site.
Information by UniProt
E3 ubiquitin-protein ligase SMURF1 antibody
Western blot - SMURF1 antibody (ab94480)
All lanes :
Anti-SMURF1 antibody (ab94480) at 1 µg/ml
Lane 1 :
HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 :
U2OS (Human osteosarcoma cell line) Whole Cell Lysate
Lane 3 :
MG-63 (Human osteosarcoma cell line) Whole Cell Lysate
Lane 4 :
Human bone tumor tissue lysate - total protein (
Lane 5 :
Saos 2 (Human epithelial-like osteosarcoma cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (
) at 1/5000 dilution
Developed using the ECL technique
Performed under reducing conditions.
Predicted band size :
Observed band size :
Additional bands at :
43 kDa. We are unsure as to the identity of these extra bands.
Exposure time :
has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"